Skip to main content
. 2020 Apr 2;222(5):863–870. doi: 10.1093/infdis/jiaa156

Table 1.

Characteristics of Study Participants

Study Period Characteristic All Randomized to Monthly SP Randomized to Monthly DP
At Enrollment Number of participants 637 311 326
Age in years, mean (SD) 24.0 (5.8) 24.0 (6.0) 23.9 (5.7)
Gestational age in weeks, mean (SD) 15.6 (2.3) 15.7 (2.4) 15.4 (2.3)
Gravidity, n (%) 1 153 (24.0%) 81 (26.1%) 72 (22.1%)
2 150 (23.6%) 65 (20.9%) 85 (26.1%)
≥3 334 (52.4%) 165 (53.1%) 169 (51.8%)
Parasite prevalence, n (%) Microscopic 330 (51.8%) 156 (50.2%) 174 (53.4%)
Microscopic or submicroscopic 524 (82.3%) 260 (83.6%) 264 (81.0%)
During Pregnancy Parasite prevalencea, n/N (%) Microscopic 1114/4348 (25.6%) 787/2110 (37.3%) 347/2238 (15.5%)
Microscopic or submicroscopic 2338/4348 (53.8%) 1496/2110 (70.9%) 842/2238 (37.6%)
Incidence of malaria, episodes per person years 0.34 0.60 0.09
At Delivery Binary measures of malaria in pregnancy, n/N (%) Maternal blood microscopy 27/635 (4.3%) 26/310 (8.4%) 1/325 (0.3%)
Placental blood microscopy 28/633 (4.4%) 27/307 (8.8%) 1/326 (0.3%)
Placental blood LAMPb 74/624 (11.9%) 67/301 (22.3%) 7/323 (2.2%)
Histopathology 284/637 (44.6%) 192/311 (61.7%) 92/326 (28.2%)
Adverse birth outcomes, n (%) Low birth weight 46 (7.2%) 23 (7.4%) 23 (7.1%)
Small for gestational age 70 (11.0%) 33 (10.6%) 37 (11.4%)
Preterm birth 37 (5.8%) 20 (6.4%) 17 (5.2%)

Abbreviations: DP, dihydroartemisinin-piperaquine; LAMP, loop-mediated isothermal amplification; SD, standard deviation; SP, sulfadoxine-pyrimethamine.

aDuring routine visits.

bLAMP of DNA.